Incidence and Risk Factors of Chest Wall Metastasis at Biopsy Sites in Patients with Malignant Pleural Mesothelioma
Authors:
- Masaki HashimotoMHMasaki Hashimoto
- Michiko YukiMYMichiko Yuki
- Kazuhiro KitajimaKKKazuhiro Kitajima
- Akihiro FukudaAFAkihiro Fukuda
- Toru NakamichiTNToru Nakamichi
- Akifumi NakamuraANAkifumi Nakamura
- Ayumi KurodaAKAyumi Kuroda
- Seiji MatsumotoSMSeiji Matsumoto
- Nobuyuki KondoNKNobuyuki Kondo
- Ayuko SatoASAyuko Sato
- Koichiro YamakadoKYKoichiro Yamakado
- Tohru TsujimuraTTTohru Tsujimura
Open Access
Abstract
To investigate the incidence and risk factors of chest wall metastasis (CWM) at biopsy sites in patients with malignant pleural mesothelioma (MPM). This retrospective cohort study was conducted in 262 consecutive MPM patients who underwent multimodal treatment in which including neoadjuvant chemotherapy (NAC) and curative-intent surgery, from August 2009 to March 2021. CWM was evaluated radiologically (r-CWM) and pathologically (p-CWM). We also investigated the risk factors of p-CWM and the consistency between r-CWM and p-CWM. Of 262 patients, 25 patients were excluded from analysis due to missing data or impossibility of evaluation. Of the eligible 237 patients, pleural biopsy was performed via video-assisted thoracoscopic surgery in 197 (83.1%) and medical thoracoscopy in 40 (16.9%). Pleurodesis was performed after pleural biopsy in 74 patients (31.2%). All patients received NAC followed by curative-intent surgery. Radiological examination showed r-CWM in 43 patients (18.1%), while pathological examination showed p-CWM in 135 patients (57.0%). The incidence of p-CWM was significantly higher in the patients who received pleurodesis after pleural biopsy (77.0% vs. 47.9%, <0.001). Multivariate logistic regression analysis for p-CWM revealed that pleurodesis is an independent risk factor of p-CWM (adjusted hazard ratio, 3.46; 95% confidence interval, 1.84–6.52, <0.001). CWM at the biopsy site was pathologically proven in more than half of the patients (57.0%) who received NAC followed by curative-intent surgery, which was higher than the numbers diagnosed by radiological examinations (p-CWM: 57.0% vs. r-CWM: 18.1%). Pleurodesis after pleural biopsy is an independent risk factor of p-CWM.Keywords
This publication has 42 references indexed in Scilit:
- Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG stage III malignant pleural mesotheliomaEuropean Journal of Cardio-Thoracic Surgery, 2012
- Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascadeCell Cycle, 2012
- Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 casesCancer, 2010
- Current Trends in Radiologic Management of Malignant Pleural MesotheliomaSeminars in Thoracic and Cardiovascular Surgery, 2009
- Local recurrence of tumor at sites of intervention in malignant pleural mesotheliomaLung Cancer, 2008
- Pleurodesis for malignant pleural effusion: talc, toxicity and where next?Thorax, 2008
- Population based epidemiology and prognosis of mesothelioma in Leeds, UKThorax, 2008
- Prevention of malignant seeding at drain sites after invasive procedures (surgery and/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesotheliomaActa Oncologica, 2008
- Prolonged survival after talc poudrage for malignant pleural mesothelioma: Case seriesRespirology, 2005
- Vascular endothelial growth factor is an autocrine growth factor in human malignant mesotheliomaThe Journal of Pathology, 2001